Telix Pharmaceuticals Limited (ASX: TLX) - ETF Exposure

Current share price for TLX : $12.850 0.34 (2.58%)⁺

Telix Pharmaceuticals Limited (TLX) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a global biopharmaceutical company engaged in the development and commercialization of targeted therapeutic and diagnostic radiopharmaceuticals, along with supporting medical technologies. Headquartered in Melbourne, Australia, Telix maintains strategic international operations across the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan.

TLX General Information ⁺

ASX Code	TLX
Website	http://www.telixpharma.com
Industry/Sector	Biotechnology
Market Cap ($M)	4,373
TLX Share Price	$12.850
Day High	$13.110
Day Low	$12.610
Last Close	$13.190
TLX Share Price Movement	$0.34 ( 2.58% )

Prices as at 16:40, 26 Oct 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to TLX

As a significant Australian company by market capitalisation, TLX is held across 24 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when TLX moves, funds like IMPQ, M1DS, MVE, VSO and FAIR that hold it can move with it.

For more concentrated exposure, ETFs such as IMPQ (eInvest Better Future (Managed Fund)) allocate about 2.8% to TLX , while the average exposure across all 24 ETFs that hold it is around 0.5% .

Top ETF holdings

eInvest Better Future (Managed Fund) (IMPQ) ~ 2.8%
Paradice Australian Mid Cap Fund Active ETF (M1DS) ~ 1.7%
VanEck S&P/ASX MidCap ETF (MVE) ~ 1.2%
Vanguard MSCI Australian Small Companies Index ETF (VSO) ~ 0.8%
BetaShares Australian Sustainability Leaders ETF (FAIR) ~ 0.8%

Last updated: ETF data and holdings as at 26 October 2026

Own TLX directly or through an ETF?

How does holding Telix Pharmaceuticals Limited (TLX) shares directly compare to ETFs that include it?

	TLX Direct	IMPQ ASX	M1DS CBOE	MVE ASX	VSO ASX	FAIR ASX
Holdings	1 company	42 holdings	56 holdings	53 holdings	204 holdings	83 holdings
TLX Weight	100%	2.8%	1.7%	1.2%	0.8%	0.8%
Diversification	Single Stock	Broad	Broad	Broad	Broad	Broad
Annual Cost	Brokerage only	-	-	0.45% p.a.	0.3% p.a.	0.49% p.a.
Approx. Yield	-	-	-	2.64%	5.04%	3.07%
Star Ratings	-	Not Rated

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not TLX's direct yield. Annual cost uses each ETF's MER.

TLX Exposure on $10,000 investment

How a $10,000 investment in Telix Pharmaceuticals Limited (TLX) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Telix Pharmaceuticals Limited (TLX)	Direct share	$12.850	-16.56%	-$1,656	$8,344
eInvest Better Future (Managed Fund) (IMPQ)	-	$3.980	0%	$0	$10,000
Paradice Australian Mid Cap Fund Active ETF (M1DS)	Equity - Australia Strategy	$5.950	0.34%	+$34	$10,034
VanEck S&P/ASX MidCap ETF (MVE)	Equity - Australia Small/Mid Cap	$43.860	-0.11%	-$11	$9,989
Vanguard MSCI Australian Small Companies Index ETF (VSO)	Equity - Australia Small/Mid Cap	$69.360	-1.99%	-$199	$9,801
BetaShares Australian Sustainability Leaders ETF (FAIR)	Equity - Australia Strategy	$18.860	2%	+$200	$10,200

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Telix Pharmaceuticals Limited (TLX) ETFs

24 ETFs hold Telix Pharmaceuticals Limited (TLX).

ETF	TLX Weight	MER	Yield
eInvest Better Future (Managed Fund) (IMPQ)	2.8%	-	-
Paradice Australian Mid Cap Fund Active ETF (M1DS)	1.7%	-	-
VanEck S&P/ASX MidCap ETF (MVE)	1.2%	0.45%	2.64%
Vanguard MSCI Australian Small Companies Index ETF (VSO)	0.8%	0.3%	5.04%
BetaShares Australian Sustainability Leaders ETF (FAIR)	0.8%	0.49%	3.07%
VanEck MSCI Australian Sustainable Equity ETF (GRNV)	0.5%	0.35%	3.56%
Global X Australia ex Financials & Resources ETF (OZXX)	0.5%	0.25%	5.52%
Betashares Australian Ex-20 Portfolio Diversifier ETF (EX20)	0.4%	0.25%	2.86%
Betashares Geared Australian Equity Fund (GEAR)	0.3%	2.11%	1.82%
Vanguard Ethically Conscious Australian Shares ETF (VETH)	0.2%	0.16%	2.87%

View all 24 ETFs

Telix Pharmaceuticals Limited (TLX) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Telix Pharmaceuticals Limited (TLX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Telix Pharmaceuticals Limited (TLX) price-sensitive announcements

TLX - Telix Reports Third Quarter 2026 Financial Performance

Telix Pharmaceuticals Limited reported Q3 2026 unaudited financial performance for the qua

Telix Pharmaceuticals Limited (TLX)
21 Oct 2026 | 8:36 AM

TLX - FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging

Telix Pharmaceuticals Limited announced that the U.S. FDA granted Fast Track designation t

Telix Pharmaceuticals Limited (TLX)
30 Sep 2026 | 8:20 AM

TLX - Telix and ITM Join Forces to Create Radiopharma Powerhouse

The presentation dated 21 September 2026 outlines Telix Pharmaceuticals Limited’s proposed

Telix Pharmaceuticals Limited (TLX)
21 Sep 2026 | 8:38 AM

TLX - Telix and ITM Join Forces to Create Radiopharma Powerhouse

Telix Pharmaceuticals Limited announced on 21 September 2026 that it had signed a strategi

Telix Pharmaceuticals Limited (TLX)
21 Sep 2026 | 8:37 AM

Telix Pharmaceuticals Limited (TLX) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID	Health Care	$4,373	Appendix 3Y William Jellison	26 Oct 2026 9:50AM	$13.190	$12.850	fallen by 2.58%
Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID	Health Care	$4,373	Appendix 3Y Change in Director Interest - D Gill	26 Oct 2026 9:47AM	$13.190	$12.850	fallen by 2.58%
Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID	Health Care	$4,373	Telix Reports Third Quarter 2026 Financial Performance	21 Oct 2026 8:36AM	$15.760	$12.850	fallen by 18.46%
Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID	Health Care	$4,373	Notification of cessation of securities - TLX	5 Oct 2026 8:23AM	$15.160	$12.850	fallen by 15.24%
Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID	Health Care	$4,373	Notification regarding unquoted securities - TLX	5 Oct 2026 8:22AM	$15.160	$12.850	fallen by 15.24%
Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID	Health Care	$4,373	Application for quotation of securities - TLX	5 Oct 2026 8:22AM	$15.160	$12.850	fallen by 15.24%

TLX Financial Summary

Year to Dec	NPAT	EPS	EPS chg (%)	PER	Yield (%)	Franking (%)
2025F	$122.66	$34.57	61.00%	82.53	0.00%	0.0%
2024F	$76.18	$21.47	5.70%	132.88	0.00%	0.0%
2023A	$65.73	$20.31	-174.80%	46.74	0.00%	0.0%

TLX Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 F	2025 F	2023 A	2024 F	2025 F	2023 A	2024 F	2025 F
CSL Limited (CSL)	$94,393M	0.7309	-0.4389	0.0602	12.1860	21.7178	20.4851	2.16%	2.17%	2.24%
Clinuvel Pharmaceuticals Limited (CUV)	$359M	-0.0696	-0.0719	0.0242	10.6587	11.4839	11.2126	0.70%	0.70%	0.70%
Mesoblast Limited (MSB)	$2,310M	-0.4501	0.0000	0.0000	0.0000	0.0000	806.8182	0.00%	0.00%	0.00%
PYC Therapeutics Limited (PYC)	$1,752M	-0.3971	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$4,489M	-1.3893	0.0000	-0.5224	0.0000	155.1765	324.8768	0.00%	0.00%	0.00%

TLX Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	231.30	7.01	3.97
Market	0.30	13.30	1.03	0.71
Sector	0.77	38.40	2.31	2.03

TLX Directors

Name	Position	Start Date
Dr Christian Peter Behrenbruch	Chief Executive Officer, Managing Director	3 Jan 2017
Ms Jann E Skinner	Non-Executive Director	19 Jun 2018
Ms Marie Elizabeth McDonald	Non-Executive Director	3 Mar 2025
Dr Mark Alexander Nelson	Non-Executive Director	17 Sep 2017
Dr Maria Rivas	Non-Executive Director	11 May 2026
Mr William (Bill) Jellison	Non-Executive Director	11 May 2026
Mr David Gill	Non-Executive Director, Non-Executive Chairman	11 May 2026

Telix Pharmaceuticals Limited (TLX) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
23 Oct 2026	GILL, David	Buy	Direct Shares	3,250	$9.194	$29,880.500
22 Oct 2026	JELLISON, William (Bill)	Buy	Indirect Shares	25,000	$9.493	$237,327.500
24 Sep 2026	GILL, David	Buy	Direct Shares	11,800	$11.310	$133,458.000

See all changes in directors' interest & trades for Telix Pharmaceuticals Limited (TLX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

TLX Management

Name	Position
Raphael Ortiz	Chief Executive Officer, Telix International
Kevin Richardson	Chief Executive Officer, Telix Precision Medicine
Richard Valeix	Chief Executive Officer, Telix Therapeutics
Marcin Firek	Company Secretary
Darren Smith	Group Chief Financial Officer
David Cade	Group Chief Medical Officer
Mary Jessel	Group Chief of Clinical Affairs
Darren Patti	Group Chief Operating Officer
Lena Moran-Adams	Group General Counsel
Meredith Crowe	Senior Vice President, People & Culture

TLX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Telix Pharmaceuticals Limited (TLX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
28,187,775 (8.30%)	State Street Corporation and subsidiaries
22,419,015 (6.60%)	JPmorgan Chase & Co. and its affiliates
20,675,000 (6.10%)	Gnosis Verwaltungsgesellschaft
20,675,000 (6.10%)	Elk River Holdings Pty Ltd

TLX Calendar of Events

Date	Event
19 August 2027	Report (Interim)
19 February 2027	Report (Annual)
19 February 2027	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us